Profile data is unavailable for this security.
About the company
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
- Revenue in USD (TTM)3.99bn
- Net income in USD463.16m
- Incorporated2005
- Employees2.80k
- LocationJazz Pharmaceuticals PLCFifth FlWaterloo Exchange, Waterloo RoadDUBLIN 4IrelandIRL
- Phone+353 16347800
- Fax+353 16347850
- Websitehttps://www.jazzpharma.com/
Mergers & acquisitions
Acquired company | JAZZ:NSQ since announced | Transaction value |
---|---|---|
Redx Pharma PLC-KRAS Inhibitor Program | -0.88% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prestige Consumer Healthcare Inc | 1.11bn | 205.95m | 3.98bn | 570.00 | 19.58 | 2.29 | 16.77 | 3.59 | 4.11 | 4.11 | 22.14 | 35.03 | 0.334 | 3.13 | 6.90 | 1,948,525.00 | 6.19 | 3.69 | 6.42 | 3.84 | 55.21 | 56.79 | 18.54 | 12.19 | 2.10 | 5.68 | 0.3779 | 0.00 | -0.21 | 2.89 | 354.34 | -- | -1.84 | -- |
Organon & Co | 6.41bn | 1.30bn | 4.13bn | 10.00k | 3.18 | 8.38 | 2.65 | 0.6446 | 5.04 | 5.04 | 24.81 | 1.91 | 0.5394 | 2.08 | 3.85 | 640,900.00 | 10.95 | 16.53 | 14.08 | 20.97 | 58.26 | 65.12 | 20.30 | 26.79 | 1.21 | 2.73 | 0.9467 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.91 | -- |
Axsome Therapeutics Inc | 291.49m | -308.55m | 4.32bn | 545.00 | -- | 41.86 | -- | 14.83 | -6.51 | -6.51 | 6.15 | 2.15 | 0.5026 | 2.31 | 3.11 | 534,842.20 | -53.20 | -64.55 | -71.90 | -82.23 | 90.30 | -- | -105.85 | -227.05 | 2.40 | -79.61 | 0.6409 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
BridgeBio Pharma Inc | 219.12m | -453.82m | 5.09bn | 550.00 | -- | -- | -- | 23.25 | -2.64 | -2.64 | 1.24 | -5.81 | 0.3376 | -- | -- | 398,407.30 | -71.11 | -72.44 | -89.59 | -89.72 | 98.91 | 94.41 | -210.62 | -1,225.66 | -- | -9.63 | 2.70 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
ADMA Biologics Inc | 330.24m | 34.79m | 5.35bn | 624.00 | 160.87 | 28.00 | 123.92 | 16.19 | 0.1406 | 0.1406 | 1.41 | 0.8079 | 0.9181 | 1.04 | 9.88 | 529,237.60 | 9.67 | -24.80 | 10.99 | -28.00 | 46.12 | 17.40 | 10.53 | -51.31 | 2.80 | 4.59 | 0.4105 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
Avidity Biosciences Inc | 10.60m | -252.45m | 5.50bn | 253.00 | -- | 4.18 | -- | 518.75 | -2.95 | -2.95 | 0.1231 | 11.17 | 0.0108 | -- | 17.92 | 41,893.28 | -25.78 | -31.61 | -27.61 | -34.45 | -- | -- | -2,381.82 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
Corcept Therapeutics Incorporated | 628.56m | 141.82m | 6.24bn | 352.00 | 46.94 | 9.74 | 43.68 | 9.93 | 1.27 | 1.27 | 5.64 | 6.12 | 0.9121 | 1.26 | 13.32 | 1,785,668.00 | 20.58 | 21.17 | 25.10 | 23.85 | 98.44 | 98.52 | 22.56 | 27.23 | 3.64 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
Elanco Animal Health Inc | 4.45bn | 205.00m | 6.96bn | 9.30k | 34.43 | 1.07 | 7.96 | 1.56 | 0.4087 | 0.4087 | 8.99 | 13.20 | 0.3224 | 1.21 | 5.09 | 478,924.70 | 1.48 | -3.27 | 1.64 | -3.65 | 54.69 | 54.28 | 4.60 | -11.53 | 1.31 | 0.9883 | 0.4005 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
Jazz Pharmaceuticals PLC | 3.99bn | 463.16m | 7.63bn | 2.80k | 17.41 | 1.79 | 6.84 | 1.91 | 7.10 | 7.10 | 60.27 | 69.01 | 0.3404 | 0.7371 | 5.91 | 1,425,969.00 | 3.97 | 1.48 | 4.46 | 1.62 | 89.37 | 88.79 | 11.65 | 4.26 | 3.74 | 2.82 | 0.5944 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
Halozyme Therapeutics, Inc. | 947.36m | 392.47m | 7.76bn | 373.00 | 20.18 | 17.13 | 16.37 | 8.19 | 3.02 | 3.02 | 7.30 | 3.56 | 0.4724 | 1.30 | 3.77 | 2,539,826.00 | 19.57 | 18.22 | 20.73 | 21.97 | 82.09 | 79.05 | 41.43 | 39.36 | 9.15 | -- | 0.7687 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
Roivant Sciences Ltd | 158.30m | 4.74bn | 8.78bn | 845.00 | 2.13 | 1.61 | 1.89 | 55.45 | 5.57 | 5.57 | 0.1979 | 7.35 | 0.0367 | 0.8018 | 2.71 | 187,340.80 | 106.95 | -- | 126.66 | -- | 90.32 | -- | 2,916.27 | -- | 27.75 | -- | 0.052 | -- | 103.65 | -- | 487.06 | -- | -- | -- |
Intra-Cellular Therapies Inc | 613.73m | -86.37m | 9.68bn | 610.00 | -- | 8.45 | -- | 15.77 | -0.8595 | -0.8595 | 6.10 | 10.80 | 0.6011 | 1.42 | 4.94 | 1,006,112.00 | -8.46 | -38.27 | -9.74 | -42.77 | 92.30 | -- | -14.07 | -128.42 | 7.51 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
Catalent Inc | 4.42bn | -413.00m | 10.78bn | 16.90k | -- | 3.04 | 140.05 | 2.44 | -2.27 | -2.27 | 24.33 | 19.57 | 0.4482 | 4.92 | 3.27 | 261,656.80 | -4.19 | 0.0124 | -4.80 | 0.014 | 21.82 | 28.93 | -9.34 | 0.0278 | 1.93 | 0.7814 | 0.5821 | -- | 2.77 | 11.71 | -307.42 | -- | 8.44 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 30 Jun 2024 | 6.16m | 9.97% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 5.39m | 8.73% |
LSV Asset Managementas of 30 Jun 2024 | 2.48m | 4.02% |
Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 2.02m | 3.27% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.02m | 3.27% |
Pacer Advisors, Inc.as of 30 Jun 2024 | 1.82m | 2.95% |
Vestal Point Capital LPas of 30 Jun 2024 | 1.50m | 2.43% |
Polaris Capital Management LLCas of 30 Jun 2024 | 1.38m | 2.23% |
JPMorgan Investment Management, Inc.as of 30 Jun 2024 | 1.36m | 2.20% |
The Baupost Group LLCas of 30 Jun 2024 | 1.27m | 2.06% |